Resumen

Objective: To evaluate the effect of liraglutide on body weight and metabolic parameters associated with cardiovascular risk in patient with or without type 2 diabetes mellitus (DM). Methods: A descriptive, observational and analytical study was performed. A review was conducted on clinical records from patients seen in a cardiology private practice, who received liraglutide as a weight -reducing supplement, combined with prescription of several life style modifications as a 2000 kcal diet in men, or 1800 kcal diet in women and moderate daily aerobic exercise (at least 30 minutes, 5 times a week) during 3 months. Data from both, diabetic and non diabetic obese patients with body mass index (BMI) >30 kg/m2 and at least two failed weight lost attempts in previous twelve months were included. Thirty eight cases meeting these criteria were selected. Results: An average of 4.8 kg of weight lost at the end of three months were observed (p<0.001). Further benefits in several cardiovascular and/or metabolic risk factors such as: increased c-HDL, decreased serum triglycerides and lowering of systolic blood pressure. Liraglutide showed an adequate safety profile, with only minor adverse reactions (nausea, dizziness, vomiting, diarrhea or constipation), which disappeared within the first two weeks of treatment. Conclusion: The effectiveness and security of liraglutide as a supplement for weight loss were demonstrated. Liraglutide also showed beneficial effects improving metabolic risk factor that leads to cardiovascular disease.

Palabras clave: Liraglutide; GLP-1; obesity; overweight; type 2 diabetes mellitus; Mexico.

2014-12-03   |   605 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.63. Abril-Junio 2014 Pags. 66-70 Med Univer 2014; 16(63)